Cargando…
Genetic and immune characteristics of multiple primary lung cancers and lung metastases
BACKGROUND: To explore the genetic and immunophenotyping heterogeneities between patients with intrapulmonary metastasis (IPM) or multiple primary lung cancer (MPLC). METHODS: Whole exome sequencing (WES) and transcriptome sequencing (RNA‐seq) were performed on the tissue and blood samples of IPM an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487821/ https://www.ncbi.nlm.nih.gov/pubmed/34510768 http://dx.doi.org/10.1111/1759-7714.14134 |
_version_ | 1784578033621925888 |
---|---|
author | Yang, Ronghua Li, Peng Wang, Dong Wang, Lingjie Yin, Jihui Yu, Baohua Li, Mengjun Wang, Sai Wang, Yongjie |
author_facet | Yang, Ronghua Li, Peng Wang, Dong Wang, Lingjie Yin, Jihui Yu, Baohua Li, Mengjun Wang, Sai Wang, Yongjie |
author_sort | Yang, Ronghua |
collection | PubMed |
description | BACKGROUND: To explore the genetic and immunophenotyping heterogeneities between patients with intrapulmonary metastasis (IPM) or multiple primary lung cancer (MPLC). METHODS: Whole exome sequencing (WES) and transcriptome sequencing (RNA‐seq) were performed on the tissue and blood samples of IPM and MPLC patients to comprehensively analyze the clonal evolution, molecular typing and immunophenotyping. RESULTS: There was no significant difference in genetic mutation, tumor mutational burden (TMB) value and mutant allele tumor heterogeneity (MATH) value between IPM and MPLC patients. Notably, the loss of heterozygosity (LOH) of human leukocyte antigen (HLA) appeared in all IPM patients, while there was also no significant difference between the two groups. In addition, expression of immune checkpoint‐related genes including CTLA‐4, BTLA, TIGIT and HAVCR2 in the MPLC group was significantly higher than those in IPM group. At the same time, 86 differentially expressed genes (DEGs) were observed between IPM and MPLC patients with transcriptome sequencing, of which 56 DEGs were upregulated and 30 were downregulated in the IPM group compared with the MPLC group. The cluster analysis revealed that the 86 DEGs could be distinguished in IPM and MPLC samples. Moreover, only the infiltration levels of CD56dim natural killer cells in the IPM group was significantly higher than that in the MPLC group, and the infiltration levels of the remaining 27 immune cell subsets were similar in both groups. CONCLUSIONS: IPM and MPLC are roughly similar in genetic and immune characteristics indicating that genomics alone may not be able to effectively distinguish between IPM and MPLC, which still needs to be comprehensively evaluated with clinical manifestations, imaging, and pathological characteristics. |
format | Online Article Text |
id | pubmed-8487821 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-84878212021-10-08 Genetic and immune characteristics of multiple primary lung cancers and lung metastases Yang, Ronghua Li, Peng Wang, Dong Wang, Lingjie Yin, Jihui Yu, Baohua Li, Mengjun Wang, Sai Wang, Yongjie Thorac Cancer Original Articles BACKGROUND: To explore the genetic and immunophenotyping heterogeneities between patients with intrapulmonary metastasis (IPM) or multiple primary lung cancer (MPLC). METHODS: Whole exome sequencing (WES) and transcriptome sequencing (RNA‐seq) were performed on the tissue and blood samples of IPM and MPLC patients to comprehensively analyze the clonal evolution, molecular typing and immunophenotyping. RESULTS: There was no significant difference in genetic mutation, tumor mutational burden (TMB) value and mutant allele tumor heterogeneity (MATH) value between IPM and MPLC patients. Notably, the loss of heterozygosity (LOH) of human leukocyte antigen (HLA) appeared in all IPM patients, while there was also no significant difference between the two groups. In addition, expression of immune checkpoint‐related genes including CTLA‐4, BTLA, TIGIT and HAVCR2 in the MPLC group was significantly higher than those in IPM group. At the same time, 86 differentially expressed genes (DEGs) were observed between IPM and MPLC patients with transcriptome sequencing, of which 56 DEGs were upregulated and 30 were downregulated in the IPM group compared with the MPLC group. The cluster analysis revealed that the 86 DEGs could be distinguished in IPM and MPLC samples. Moreover, only the infiltration levels of CD56dim natural killer cells in the IPM group was significantly higher than that in the MPLC group, and the infiltration levels of the remaining 27 immune cell subsets were similar in both groups. CONCLUSIONS: IPM and MPLC are roughly similar in genetic and immune characteristics indicating that genomics alone may not be able to effectively distinguish between IPM and MPLC, which still needs to be comprehensively evaluated with clinical manifestations, imaging, and pathological characteristics. John Wiley & Sons Australia, Ltd 2021-09-12 2021-10 /pmc/articles/PMC8487821/ /pubmed/34510768 http://dx.doi.org/10.1111/1759-7714.14134 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yang, Ronghua Li, Peng Wang, Dong Wang, Lingjie Yin, Jihui Yu, Baohua Li, Mengjun Wang, Sai Wang, Yongjie Genetic and immune characteristics of multiple primary lung cancers and lung metastases |
title | Genetic and immune characteristics of multiple primary lung cancers and lung metastases |
title_full | Genetic and immune characteristics of multiple primary lung cancers and lung metastases |
title_fullStr | Genetic and immune characteristics of multiple primary lung cancers and lung metastases |
title_full_unstemmed | Genetic and immune characteristics of multiple primary lung cancers and lung metastases |
title_short | Genetic and immune characteristics of multiple primary lung cancers and lung metastases |
title_sort | genetic and immune characteristics of multiple primary lung cancers and lung metastases |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487821/ https://www.ncbi.nlm.nih.gov/pubmed/34510768 http://dx.doi.org/10.1111/1759-7714.14134 |
work_keys_str_mv | AT yangronghua geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT lipeng geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT wangdong geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT wanglingjie geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT yinjihui geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT yubaohua geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT limengjun geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT wangsai geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases AT wangyongjie geneticandimmunecharacteristicsofmultipleprimarylungcancersandlungmetastases |